provider image
Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
Skip to main content

Mektovi

binimetinib
Used for Melanoma
Used for Melanoma

Mektovi (binimetinib) is a MEK inhibitor that's used to treat adults with melanoma (a type of skin cancer) or non-small cell lung cancer (NSCLC). These cancers must have a certain mutation known as a BRAF mutation. Treatment with Mektovi (binimetinib) is convenient because it’s a tablet that's taken by mouth, but it must be taken with another medication called Braftovi (encorafenib) to treat the cancer better. Mektovi (binimetinib) can cause side effects such as nausea, diarrhea, and serious eye problems.

Last reviewed on December 12, 2023
basics-icon

What is Mektovi (binimetinib)?

What is Mektovi (binimetinib) used for?

How Mektovi (binimetinib) works

Mektovi (binimetinib) is a kinase inhibitor known as a MEK inhibitor. The MEK protein is part of a whole chain of proteins that help cells grow. By blocking MEK, this medication helps stop tumor growth.

Mektovi (binimetinib) is taken together with an anticancer medication called Braftovi (encorafenib) that specifically targets another protein in this chain (the BRAF protein). When the BRAF protein is mutated, the cancer grows uncontrollably and can spread more quickly.

By blocking two different proteins in this pathway, Mektovi (binimetinib) and Braftovi (encorafenib) work together to stop the cancer from growing and spreading.

Drug Facts

Common BrandsMektovi
Drug ClassMEK inhibitor
Controlled Substance ClassificationNot a controlled medication
Generic StatusNo lower-cost generic available
AvailabilityPrescription only
basics-icon

What are the side effects of Mektovi (binimetinib)?

The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.

Common Side Effects

  • Higher creatinine levels in the blood (93%)
  • Higher liver enzymes in the blood (up to 45%)
  • Tiredness (43%)
  • Nausea (41%)
  • Diarrhea (36%)
  • Anemia (36%)
  • Vomiting (30%)
  • Stomach pain (28%)
  • Constipation (22%)
  • Rash (22%)
  • Vision changes (20%)

Other Side Effects

  • Fever
  • Feeling dizzy
  • Swelling in the lower leg or ankle
  • Higher blood pressure
  • Lower white blood cell count
Side effects listed were reported by people taking Mektovi (binimetinib) with Braftovi (encorafenib) for melanoma. Side effects might differ for people with non-small cell lung cancer.

Serious Side Effects

Contact your healthcare provider immediately if you experience any of the following.
  • Blood clots: sudden trouble breathing; chest pain; swelling in one arm or one leg, often with warm, red skin
  • Serious lung problems: sudden cough, trouble breathing, tightness in chest, fever
  • Bleeding: blood in stool, bleeding from rectum, sudden headache

Source: DailyMed

The following side effects have also been reported

Side effects that you should report to your care team as soon as possible:

  • Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat
  • Bleeding—bloody or black, tar-like stools, vomiting blood or brown material that looks like coffee grounds, red or dark brown urine, small red or purple spots on skin, unusual bruising or bleeding
  • Blood clot—pain, swelling, or warmth in the leg, shortness of breath, chest pain
  • Blurry vision, vision loss, seeing wavy or bent objects or blind spots with dark, light, or flashing spots
  • Dry cough, shortness of breath or trouble breathing
  • Eye pain, redness, irritation, or discharge with blurry or decreased vision
  • Heart failure—shortness of breath, swelling of the ankles, feet, or hands, sudden weight gain, unusual weakness or fatigue
  • Liver injury—right upper belly pain, loss of appetite, nausea, light-colored stool, dark yellow or brown urine, yellowing skin or eyes, unusual weakness or fatigue
  • Muscle injury—unusual weakness or fatigue, muscle pain, dark yellow or brown urine, decrease in amount of urine

Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):

pros-and-cons

Pros and cons of Mektovi (binimetinib)

thumbs-up

Pros

Taken by mouth, so it’s a good option for people who don’t like needles

Can take with or without food

Works in a more specific targeted way than traditional chemotherapy

Recommended treatment option for people with BRAF-mutated melanoma

thumbs-down

Cons

Must take with a second medication, so might be less convenient

Often causes tiredness, nausea, and diarrhea (usually mild)

Might cause vision changes, which can be signs of serious eye problems

Requires regular blood tests to check for side effects

pharmacist-tips

Pharmacist tips for Mektovi (binimetinib)

pharmacist
  • Take Mektovi (binimetinib) twice a day, around 12 hours apart. You’ll need to take it with Braftovi (encorafenib), which is taken once a day. You can take both medications with or without food.

    • You might have mild nausea while you're taking Mektovi (binimetinib). Your provider might suggest you take a medication to prevent nausea before each dose. Tell your provider if you have nausea while you're taking Mektovi (binimetinib).

      • If you miss a dose of Mektovi (binimetinib) and you have more than 6 hours until your next usual dose time, you should take the dose. But if it’s less than 6 hours until the next time you typically take your dose, skip the dose you missed.

        • Ask your provider about the best way to safely handle and throw away Mektovi (binimetinib). Anticancer medications can be harmful to people who handle or come in contact with them. You should store the medication up and away, so children and pets won’t be able to reach it.

          • It isn't recommended to breastfeed while you're taking Mektovi (binimetinib). We don’t know whether the medication is found in breast milk and whether it affects breastfed babies. But because of the possible risks to a baby, it’s best to avoid nursing if you’re taking Mektovi (binimetinib) and for 3 days after the last dose.

            faqs

            Frequently asked questions about Mektovi (binimetinib)

            How long does Braftovi (encorafenib) and Mektovi (binimetinib) work?
            Each person's cancer is different and will respond differently to Braftovi (encorafenib) and Mektovi (binimetinib) treatment. So it's hard to say for sure how long treatment will work for your cancer. In studies, some people with BRAF-mutated melanoma had a response to this cancer treatment (i.e., some improvement in cancer size) for 16.5 months. And in a study for BRAF-mutated non-small cell lung cancer, some people had a response to Braftovi (encorafenib) and Mektovi (binimetinib) treatment for at least 6 months to a year. Make sure to go to your follow-up visits on time so your care team can check how well treatment is working for your cancer.
            Can Braftovi (encorafenib) and Mektovi (binimetinib) cure melanoma?
            No, treatment with Braftovi (encorafenib) and Mektovi (binimetinib) can't cure melanoma. But these medications work together to help slow or stop the cancer from growing, spreading, and getting worse. Follow up with your providers so they can check your progress during treatment with Braftovi (encorafenib) and Mektovi (binimetinib).
            Is Mektovi (binimetinib) a chemotherapy drug?
            No, Mektovi (binimetinib) isn’t chemotherapy. Chemotherapy kills cells in your body that grow quickly, such as cancer cells as well as normal, healthy cells. But Mektovi (binimetinib) is a type of targeted therapy called a MEK inhibitor. It works differently than chemotherapy. This medication works by targeting and blocking a specific protein in cancer cells called MEK that usually helps cancer cells grow. By targeting and blocking the MEK protein, Mektovi (binimetinib) helps slow cancer growth in a more precise way.
            Is Mektovi (binimetinib) immunotherapy?
            No, Mektovi (binimetinib) isn't considered immunotherapy because how the medication works doesn't involve the immune system. Immunotherapy helps turn on or activate the immune system so it can recognize, attack, and kill abnormal cells in the body, such as cancer cells, better. Mektovi (binimetinib) is a type of targeted therapy called a MEK inhibitor that works differently than immunotherapy. It targets and blocks a specific protein in cancer cells called MEK that normally helps them grow. By targeting and blocking the MEK protein, Mektovi (binimetinib) helps slow cancer growth.
            How is Mektovi (binimetinib) administered?
            Mektovi (binimetinib) comes as tablets that you swallow. Take Mektovi (binimetinib) twice a day (around 12 hours apart), with or without food. Each tablet contains 15 mg of Mektovi (binimetinib). Depending on your dose, you might need to take more than one tablet of Mektovi (binimetinib) each time you take the medication. For example, the typical dose is 45 mg (3 tablets) twice a day. Keep in mind that Mektovi (binimetinib) must be used with another cancer medication called Braftovi (encorafenib), which is taken once a day. Speak with your care team if you need help planning when to take your cancer medications throughout the day.
            Does Mektovi (binimetinib) cause weakness?
            Feeling weak or tired is a common side effect of Mektovi (binimetinib). In clinical studies, 43% of people with BRAF-mutated melanoma who took Mektovi (binimetinib) with Braftovi (encorafenib) reported feeling weak or tired during treatment. And 61% of people with BRAF-mutated non-small cell lung cancer reported this side effect during combination treatment as well. Let your care team know if you're feeling very weak or tired while you're taking Mektovi (binimetinib) with Braftovi (encorafenib), especially if it's affecting your daily activities.
            Why does Mektovi (binimetinib) have to be taken with Braftovi (encorafenib)?
            Mektovi (binimetinib) works by blocking a specific protein inside cancer cells that’s important for tumor growth called MEK. As a result, cancer cells can’t grow or spread as well. But there are other proteins in cancer cells, such as BRAF, that also help the tumor grow. While Mektovi (binimetinib) blocks MEK, Braftovi (encorafenib) blocks BRAF. Using two medications at the same time that block different proteins involved in tumor growth helps kill cancer cells better.
            Will I lose my hair if I take Mektovi (binimetinib)?
            Typically, people who take Mektovi (binimetinib) don’t lose their hair. If you notice any hair loss during treatment, talk to your provider because there can be other causes of hair loss.
            Does Mektovi (binimetinib) cause heart problems?
            While it doesn’t happen very often, some people taking Mektovi (binimetinib) along with Braftovi (encorafenib) developed a heart condition that affected how well their heart pumps. When the heart doesn’t pump as well, some people don’t have any symptoms, but others might feel tired, have trouble breathing, or notice swelling in their legs. For some people, this side effect gets better or goes away with a pause in Mektovi (binimetinib) treatment. But if it’s serious, sometimes the medication must be stopped. You’ll need imaging scans of your heart done regularly during treatment so your provider can check your heart function.
            How long will I take Mektovi (binimetinib)?
            How long you take Mektovi (binimetinib) depends on several factors, such as how well the medication is working to treat your skin cancer and how well you tolerate its side effects. Your provider will determine how well Mektovi (binimetinib) is working by regularly checking scan results. Though they can be bothersome, most of the common side effects, like tiredness, nausea, and diarrhea, aren’t serious. But more serious side effects, like vision changes, lung problems, and bleeding, require follow up with your provider. Your provider might want to pause or stop Mektovi (binimetinib) to keep you safe. Make sure to take Mektovi (binimetinib) as instructed by your provider. Don’t stop taking the medication without first discussing it with your provider.
            GoodRxEducationalIcon

            How to save using GoodRx

            Compare Prices
            1. Compare PricesSpecify your dosage and quantity to find out exactly how much you can save.
            Select your free coupon
            2. Select your free couponYou can use the displayed coupon, or compare prices at other pharmacies near you.
            Show coupon to your pharmacist
            3. Show coupon to your pharmacistPresent your printed or electronic coupon when you pick up your prescription.
            Get free couponLearn more
            warings-icon

            What are the risks and warnings for Mektovi (binimetinib)?

            Mektovi (binimetinib) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.

            risk-warning

            Risk of new cancers

            There's a risk that new cancers can appear when you take Mektovi (binimetinib) with Braftovi (encorafenib). In clinical studies, a few people who took these two medications together reported having certain types of skin cancer. Your care team will check for new cancers often. This includes examining you before treatment, while you're taking the medications, and after you've stopped treatment. Tell your provider if you have an unexplained fever, feel very tired, have swollen lymph nodes in your neck or armpits, or spots or moles on your skin that seem unusual.

            risk-warning

            Serious heart problems

            Though uncommon, some people taking Mektovi (binimetinib) with Braftovi (encorafenib) developed a heart condition that happens when the heart doesn’t pump as well. Some people with this heart problem might not feel anything. But others might have symptoms like tiredness, trouble breathing, and swelling in the legs.

            Your provider will monitor how well your heart is pumping through imaging called an echocardiogram (echo). You’ll usually need imaging scans of your heart every 2 to 3 months while you’re taking Mektovi (binimetinib). You might need to pause or stop Mektovi (binimetinib) if the scans show that your heart isn’t pumping as well as it should or if you have related symptoms while you’re taking the medication.

            risk-warning

            Blood clots

            A small number of people developed blood clots while they were taking Mektovi (binimetinib) and Braftovi (encorafenib). These blood clots can include those that happen in the arm or leg (deep vein thrombosis or DVT). More seriously, blood clots have also happened in the lung (pulmonary embolism or PE). Seek medical attention right away if you have sudden chest pain, trouble breathing, or swelling in one arm or leg. These can be signs that you have a blood clot.

            risk-warning

            Serious eye problems

            Treatment with Mektovi (binimetinib) and Braftovi (encorafenib) can cause several different kinds of eye problems. The most commonly reported problem is a buildup of fluid in the back of the eye (serous retinopathy). This sometimes led to retinal detachment or macular edema. Though less common, some people also had blood clots in eye veins or swelling inside the eye. Your provider will check your vision or refer you to an ophthalmologist while you’re taking Mektovi (binimetinib). Tell your provider if you have any vision changes during treatment.

            risk-warning

            Serious lung problems

            Though rare, some people taking Mektovi (binimetinib) with Braftovi (encorafenib) have had a serious lung problem called interstitial lung disease (ILD). Talk to your provider right away if you have sudden or worsening cough, trouble breathing, and fever. You might have to pause or stop Mektovi (binimetinib) while your provider figures out the cause.

            risk-warning

            Liver problems

            Some people taking Mektovi (binimetinib) and Braftovi (encorafenib) together have had blood test results showing high levels of liver enzymes. These lab results can suggest liver problems. During treatment, your provider will monitor your liver health on a regular basis, usually every month. And if your levels are concerning, you might need to pause or stop Mektovi (binimetinib) while your provider looks into it.

            Most people don’t feel any noticeable symptoms when they have high liver enzyme levels happens, so it’s important to keep up with your lab work regularly. Call your provider right away if you have stomach pain, yellowish skin, or yellow around the whites of your eyes, as these can be symptoms of liver problems.

            risk-warning

            Muscle problems

            Treatment with Mektovi (binimetinib) and Braftovi (encorafenib) can raise the level of creatine phosphokinase (CPK) in your blood. This can suggest that you have muscle damage. You’ll need to get blood work done periodically during treatment so your provider can keep track of your CPK levels. But let your provider know if you have muscle pain or very dark, reddish-brown urine, as this can be a sign of a rare muscle condition called rhabdomyolysis. Your provider might pause or stop Mektovi (binimetinib) depending on how severe your symptoms are.

            risk-warning

            Bleeding

            Some people taking Mektovi (binimetinib) together with Braftovi (encorafenib) have experienced bleeding, usually in their gut. Tell your provider right away if you have blood in your stool, bleeding from your rectum, or bloody hemorrhoids. You might need to pause or stop Mektovi (binimetinib) while your provider looks into it.

            risk-warning

            Harm to unborn baby

            Based on animal studies, Mektovi (binimetinib) might harm an unborn baby or raise the risk for miscarriage (pregnancy loss). Because of these risks, if you’re able to get pregnant, your provider might ask for a negative pregnancy test before you start taking Mektovi (binimetinib). Then, you should use birth control during treatment and for at least 30 days after the last dose. Let your provider know if you become pregnant during treatment.

            dosage

            Mektovi (binimetinib) dosage forms

            Typical dosing for Mektovi (binimetinib)

            The usual dose is 45 mg by mouth twice a day (about 12 hours apart).

            Your dose might differ if you have moderate or severe liver problems. Your provider might also recommend taking a lower dose if you have certain side effects.

            alternatives

            What are alternatives to Mektovi (binimetinib)?

            There are a number of medications that your doctor can prescribe in place of Mektovi (binimetinib). Compare a few possible alternatives below.
            Mektovi (binimetinib)
            Used for:
            Used for:
            Used for:
            • Melanoma with certain BRAF mutations

            • Metastatic non-small cell lung cancer (NSCLC) with a certain BRAF mutation, used with Tafinlar (dabrafenib)

            • Metastatic anaplastic thyroid cancer (ATC) with a certain BRAF mutation, used with Tafinlar (dabrafenib)

            • Solid tumors with a certain BRAF mutation that have spread or can’t be removed by surgery, used with Tafinlar (dabrafenib)

            • Low-grade glioma (LGG) with a certain BRAF mutation, used with Tafinlar (dabrafenib)

            Get savings updates for Mektovi (binimetinib)

            Receive price alerts, news, and other messages from GoodRx about Mektovi (binimetinib) and other healthcare topics and relevant savings offers.

            By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.

            References

            Best studies we found

            Akinleye, A., et al. (2013). MEK and the inhibitors: From bench to bedside. Journal of Hematology & Oncology.

            American Cancer Society. (2019). Chemotherapy safety.

            American Cancer Society. (2021). Targeted drug therapy for kidney cancer.

            View All References (15)

            American Cancer Society. (2022). Gene changes and cancer.

            American Lung Association. (n.d.). Interstitial lung disease (ILD).

            Array BioPharma Inc. (2023). Mektovi- binimetinib tablet, film coated [package insert]. DailyMed.

            ASCO Post. (2018). FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations.

            Bakri, S. J., et al. (n.d.). Central serous chorioretinopathy. American Society of Retina Specialists.

            Marranci, A., et al. (2017). The landscape of BRAF transcript and protein variants in human cancer. Molecular Cancer.

            MedlinePlus. (2023). Creatine kinase.

            Mincu, R. I., et al. (2019). Cardiovascular adverse events associated With BRAF and MEK inhibitors: A systematic review and meta-analysis. JAMA Network Open.

            National Cancer Institute. (n.d.). BRAF V600 mutation.

            National Cancer Institute. (n.d.). MEK inhibitor.

            National Cancer Institute. (2023). Non-small cell lung cancer treatment (PDQ®)–Patient version.

            National Comprehensive Cancer Network. (2023). Melanoma.

            National Eye Institute. (2023). Macular edema.

            Riely, G. J., et al. (2023). Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non–small-cell lung cancer. Journal of Clinical Oncology.

            Stjepanovic, N., et al. (2016). Ocular toxicities of MEK inhibitors and other targeted therapies. Annals of Oncology.

            GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.
            Was this page helpful?

            Browse medications

            View All

            Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.